122 related articles for article (PubMed ID: 7733638)
1. Reduction of cisplatin cytotoxicity on human lung cancer cell lines with N-myc amplification by pretreatment with N-myc antisense oligodeoxynucleotides.
Mizushima Y; Kashii T; Kobayashi M
Anticancer Res; 1995; 15(1):37-43. PubMed ID: 7733638
[TBL] [Abstract][Full Text] [Related]
2. Effects of c-myc oncogene modulation on drug resistance in human small cell lung carcinoma cell lines.
Van Waardenburg RC; Prins J; Meijer C; Uges DR; De Vries EG; Mulder NH
Anticancer Res; 1996; 16(4A):1963-70. PubMed ID: 8712728
[TBL] [Abstract][Full Text] [Related]
3. c-myc antisense oligodeoxynucleotides enhance the efficacy of cisplatin in melanoma chemotherapy in vitro and in nude mice.
Citro G; D'Agnano I; Leonetti C; Perini R; Bucci B; Zon G; Calabretta B; Zupi G
Cancer Res; 1998 Jan; 58(2):283-9. PubMed ID: 9443406
[TBL] [Abstract][Full Text] [Related]
4. Increase of cisplatin sensitivity by c-myc antisense oligodeoxynucleotides in a human metastatic melanoma inherently resistant to cisplatin.
Leonetti C; Biroccio A; Candiloro A; Citro G; Fornari C; Mottolese M; Del Bufalo D; Zupi G
Clin Cancer Res; 1999 Sep; 5(9):2588-95. PubMed ID: 10499637
[TBL] [Abstract][Full Text] [Related]
5. Modulation of cellular functions in retroorbital fibroblasts using antisense oligonucleotides targeting the c-myc protooncogene.
Heufelder AE; Bahn RS
Invest Ophthalmol Vis Sci; 1995 Jun; 36(7):1420-32. PubMed ID: 7775120
[TBL] [Abstract][Full Text] [Related]
6. An oligomer complementary to the 5' end region of MDR1 gene decreases resistance to doxorubicin of human adenocarcinoma-resistant cells.
Corrias MV; Tonini GP
Anticancer Res; 1992; 12(5):1431-8. PubMed ID: 1444203
[TBL] [Abstract][Full Text] [Related]
7. Cationic lipids reduce time and dose of c-myc antisense oligodeoxynucleotides required to specifically inhibit Burkitt's lymphoma cell growth.
Williams SA; Chang L; Buzby JS; Suen Y; Cairo MS
Leukemia; 1996 Dec; 10(12):1980-9. PubMed ID: 8946941
[TBL] [Abstract][Full Text] [Related]
8. Contribution of sequence and phosphorothioate content to inhibition of cell growth and adhesion caused by c-myc antisense oligomers.
Chavany C; Connell Y; Neckers L
Mol Pharmacol; 1995 Oct; 48(4):738-46. PubMed ID: 7476902
[TBL] [Abstract][Full Text] [Related]
9. Effect of MDR1 phosphorothioate antisense oligodeoxynucleotides in multidrug-resistant human tumor cell lines and xenografts.
Ramachandran C; Wellham LL
Anticancer Res; 2003; 23(3B):2681-90. PubMed ID: 12894558
[TBL] [Abstract][Full Text] [Related]
10. Inhibition of vascular smooth muscle cell proliferation in vitro and in vivo by c-myc antisense oligodeoxynucleotides.
Bennett MR; Anglin S; McEwan JR; Jagoe R; Newby AC; Evan GI
J Clin Invest; 1994 Feb; 93(2):820-8. PubMed ID: 8113414
[TBL] [Abstract][Full Text] [Related]
11. Inhibition of proliferation by L-myc antisense DNA for the translational initiation site in human small cell lung cancer.
Dosaka-Akita H; Akie K; Hiroumi H; Kinoshita I; Kawakami Y; Murakami A
Cancer Res; 1995 Apr; 55(7):1559-64. PubMed ID: 7882365
[TBL] [Abstract][Full Text] [Related]
12. Effects of c-myc oncogene modulation on differentiation of human small cell lung carcinoma cell lines.
van Waardenburg RC; Meijer C; Pinto-Sietsma SJ; de Vries EG; Timens W; Mulder NM
Anticancer Res; 1998; 18(1A):91-5. PubMed ID: 9568061
[TBL] [Abstract][Full Text] [Related]
13. Antitumor efficacy of bcl-2 and c-myc antisense oligonucleotides in combination with cisplatin in human melanoma xenografts: relevance of the administration sequence.
Zupi G; Scarsella M; Semple SC; Mottolese M; Natali PG; Leonetti C
Clin Cancer Res; 2005 Mar; 11(5):1990-8. PubMed ID: 15756025
[TBL] [Abstract][Full Text] [Related]
14. Insulin-like growth factor binding protein 3 mediates retinoic acid- and transforming growth factor beta2-induced growth inhibition in human breast cancer cells.
Gucev ZS; Oh Y; Kelley KM; Rosenfeld RG
Cancer Res; 1996 Apr; 56(7):1545-50. PubMed ID: 8603400
[TBL] [Abstract][Full Text] [Related]
15. c-myc antisense oligodeoxyribonucleotides inhibit proliferation of non-small cell lung cancer.
Robinson LA; Smith LJ; Fontaine MP; Kay HD; Mountjoy CP; Pirruccello SJ
Ann Thorac Surg; 1995 Dec; 60(6):1583-91. PubMed ID: 8787447
[TBL] [Abstract][Full Text] [Related]
16. Inhibition of growth of human breast carcinoma cells by an antisense oligonucleotide targeted to the transferrin receptor gene.
Yang DC; Jiang XP; Elliott RL; Head JF
Anticancer Res; 2001; 21(3B):1777-87. PubMed ID: 11497259
[TBL] [Abstract][Full Text] [Related]
17. Antisense TRPM-2 oligodeoxynucleotides chemosensitize human androgen-independent PC-3 prostate cancer cells both in vitro and in vivo.
Miyake H; Chi KN; Gleave ME
Clin Cancer Res; 2000 May; 6(5):1655-63. PubMed ID: 10815883
[TBL] [Abstract][Full Text] [Related]
18. Alterations of c-myc expression by antisense oligodeoxynucleotides enhance the induction of apoptosis in HL-60 cells.
Kimura S; Maekawa T; Hirakawa K; Murakami A; Abe T
Cancer Res; 1995 Mar; 55(6):1379-84. PubMed ID: 7882339
[TBL] [Abstract][Full Text] [Related]
19. Inhibitory effect of EGFR antisense oligodeoxynucleotide on human hepatoma cell line.
Gong ZB; Liu JM; Li YM
Hepatobiliary Pancreat Dis Int; 2005 Aug; 4(3):433-6. PubMed ID: 16109531
[TBL] [Abstract][Full Text] [Related]
20. C-myc antisense oligodeoxynucleotides can induce apoptosis and down-regulate Fas expression in rheumatoid synoviocytes.
Hashiramoto A; Sano H; Maekawa T; Kawahito Y; Kimura S; Kusaka Y; Wilder RL; Kato H; Kondo M; Nakajima H
Arthritis Rheum; 1999 May; 42(5):954-62. PubMed ID: 10323451
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
